EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

p21 Promoter Methylation Is Vital for the Anticancer Activity of Withaferin A

Andrew Brane iD, Madeline Sutko, Trygve O Tollefsbol iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26031210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Andrew Brane und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Alabama at Birmingham, 3100 Science & Engineering Complex-East Science Hall, 902 14th Street South, Birmingham, …. Hauptthemen laut MEDLINE: Withanolides, DNA Methylation, Cyclin-Dependent Kinase Inhibitor p21, Promoter Regions, Genetic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is a widespread malignancy that affects the lives of millions of women each year, and its resulting financial and healthcare hardships cannot be overstated. These issues, in combination with side effects and obstacles associated with the current standard of care, generate considerable interest in new potential targets for treatment as well as means for BC prevention. One potential preventive compound is Withaferin A (WFA), a traditional medicinal compound found in winter cherries. WFA has shown promise as an anticancer agent and is thought to act primarily through its effects on the epigenome, including, in particular, the methylome. However, the relative importance of specific genes’ methylation states to WFA function remains unclear. To address this, we utilized human BC cell lines in combination with CRISPR-dCas9 fused to DNA methylation modifiers (i.e., epigenetic editors) to elucidate the importance of specific genes’ promoter methylation states to WFA function and cancer cell viability. We found that targeted demethylation of promoters of the tumor suppressors p21 and p53 within MDA-MB-231/MCF7 cells resulted in around 1.7×/1.5× and 1.2×/1.3× increases in expression, respectively. Targeted methylation of the promoter of the oncogene CCND1 within MDA-MB-231/MCF7 cells resulted in 0.5×/0.8× decreases in gene expression. These changes to p21, p53, and CCND1 were also associated with decreases in cell viability of around 25%/50%, 5%/35%, and 12%/16%, respectively, for MDA-MB-231/MCF7 cells. When given in combination with WFA in both p53 mutant and wild type cells, we discovered that targeted methylation of the p21 promoter was able to modulate the anticancer effects of WFA, while targeted methylation or demethylation of the promoters of p53 and CCND1 had no significant effect on viability decreases from WFA treatment. Taken together, these results indicate that p21, p53, and CCND1 may be important targets for future in vivo studies that may lead to epigenetic editing therapies and that WFA may have utility in the prevention of BC through its effect on p21 promoter methylation independent of p53 function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WithanolidesDNA MethylationCyclin-Dependent Kinase Inhibitor p21Promoter Regions, GeneticBreast NeoplasmsAntineoplastic AgentsHumansMCF-7 CellsCell Line, TumorGene Expression Regulation, NeoplasticTumor Suppressor Protein p53FemaleCell SurvivalEpigenesis, Genetic

Stichwörter der Autor:innen

CRISPR-dCas9DNA methylationWithaferin Abreast cancerepigeneticsphytochemicalsprevention

Substanzen

Withanolideswithaferin ACyclin-Dependent Kinase Inhibitor p21CDKN1A protein, humanTumor Suppressor Protein p53Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Biology, University of Alabama at Birmingham, 3100 Science & Engineering Complex-East Science Hall, 902 14th Street South, Birmingham, AL 35205, USA.
  • Comprehensive Cancer Center, University of Alabama at Birmingham, 1802 6th Avenue South, Birmingham, AL 35294, USA.
  • Integrative Center for Aging Research, University of Alabama at Birmingham, 933 19th Street South, Birmingham, AL 35294, USA.
  • Nutrition Obesity Research Center, University of Alabama at Birmingham, 1675 University Blvd, Birmingham, AL 35294, USA.
  • Comprehensive Diabetes Center, University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL 35294, USA.

ORCID-Profile: Andrew Brane, Trygve O Tollefsbol

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • National Cancer Institute, National Institutes of Health

Zitieren

APA

Brane, A., Sutko, M., & Tollefsbol, T. O. (2025). p21 Promoter Methylation Is Vital for the Anticancer Activity of Withaferin A. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26031210

Vancouver

Brane A, Sutko M, Tollefsbol TO. p21 Promoter Methylation Is Vital for the Anticancer Activity of Withaferin A. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26031210

BibTeX
@article{Brane2025,
  author = {Brane, Andrew and Sutko, Madeline and Tollefsbol, Trygve O},
  title = {p21 Promoter Methylation Is Vital for the Anticancer Activity of Withaferin A},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26031210}
}
Kostenlos starten →